List view / Grid view
NICE has raised the cost-effectiveness thresholds for ultra-rare disease drugs under its Highly Specialised Technology programme – a move welcomed by patient advocates and biotech leaders.
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
AI is increasingly used in drug discovery, but hidden bias and ‘black box’ models threaten trust and transparency. This article explores how explainable AI can turn opaque predictions into clear, accountable insights.
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
King’s College London and Medicines Discovery Catapult have secured £400,000 from The Brain Tumour Charity to fast-track a new drug delivery approach for glioblastoma, the most aggressive brain cancer. The project will support preclinical studies to move potential treatments closer to patients.
Quantitative Systems Pharmacology (QSP) is fast becoming a standard tool in drug development, offering a human-relevant way to predict drug effects before the clinic. Dr Josh Apgar of Certara explains how it is helping to cut reliance on animal testing and speed discovery.
3 September 2025 | By Eurofins DiscoverX
Join this webinar to learn how WRPRFa, a novel peptide tool selective for ASIC3, advances pain research and supports drug discovery in peripheral nociceptors.
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
Brazilian researchers have developed a new Zika virus vaccine that is safe and effective in mice – protecting against both brain inflammation and testicular damage while avoiding cross-reactions with dengue.
What if familiar lab formats could be redesigned to remove the weak points in permeability and absorbance testing? This article explores how design choices in common consumables can improve both speed and reproducibility in early-stage research.
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
